DB17844Investigational
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists... Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
- Also known as
- MCO-010 · VMCO-1 · vMCO-I
- Code names
- vMCO-010
Resolves to
Compound
What you can answer from here — as of November 27, 2025
Which companies are running trials of Sonpiretigene isteparvovec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account